This Article Full Text Full Text (PDF) All Versions of this Article: 106/23/2877    most recent 01.CIR.0000044388.19119.02v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ng, L. L. Articles by Davies, J. E. Search for Related Content PubMed PubMed Citation Articles by Ng, L. L. Articles by Davies, J. E. Related Collections Congestive

(Circulation. 2002;106:2877.)
© 2002 American Heart Association, Inc.

Brief Rapid Communications

Plasma Urotensin in Human Systolic Heart Failure

Leong L. Ng, MD; Ian Loke, MB; Russell J. O’Brien, MB; Iain B. Squire, MD; Joan E. Davies, PhD

From the Department of Medicine and Therapeutics, University of Leicester, Leicester, UK.

Correspondence to Prof Leong Ng, Department of Medicine and Therapeutics, Leicester Royal Infirmary, Leicester LE2 7LX, UK. E-mail lln1{at}le.ac.uk

Background— Human urotensin II (UTN) has potent vasoactive and cardiostimulatory effects, acting on the G protein–linked receptor GPR14. Myocardial UTN expression is upregulated in heart failure, and UTN stimulates myocardial expression of the natriuretic peptides. We investigated plasma UTN levels in heart failure (HF; left ventricular systolic dysfunction) in comparison with plasma N-terminal pro-brain natriuretic peptide (N-BNP) levels.

Methods and Results— N-BNP and UTN were measured in plasma from 126 patients with HF and 220 age- and sex-matched controls. Both peptides were elevated in plasma of HF patients and were correlated (r_s=0.35, P<0.001). In contrast to N-BNP, there was no relationship of plasma UTN with New York Heart Association (NYHA) class. Although plasma N-BNP showed a positive relationship with age and female sex, there was no such age-dependent change in plasma UTN, and control women had lower levels compared with control men. Receiver operating characteristic curves for the diagnosis of HF had areas of 0.90 and 0.86 for N-BNP and UTN, respectively (P<0.001 for both). Receiver operating characteristic curve area for diagnosis of NYHA class I HF with UTN was better than that with N-BNP.

Conclusions— Plasma UTN is elevated in HF, which suggests a pathophysiological role for this peptide. Plasma UTN may be a useful alternative to N-BNP in the diagnosis of HF, inasmuch as its levels are elevated irrespective of age, sex, or NYHA class.

Key Words: heart failure • diagnosis • natriuretic peptides

This article has been cited by other articles:

				Y.-H. Chen, T. G. Yandle, A. M. Richards, and S. C. Palmer Urotensin II Immunoreactivity in the Human Circulation: Evidence for Widespread Tissue Release Clin. Chem., November 1, 2009; 55(11): 2040 - 2048. [Abstract] [Full Text] [PDF]

				A. D. Leonard, J. P. Thompson, E. L. Hutchinson, S. P. Young, J. McDonald, J. Swanevelder, and D. G. Lambert Urotensin II receptor expression in human right atrium and aorta: effects of ischaemic heart disease Br. J. Anaesth., April 1, 2009; 102(4): 477 - 484. [Abstract] [Full Text] [PDF]

				M. P. Quaile, H. Kubo, C. L. Kimbrough, S. A. Douglas, and K. B. Margulies Direct Inotropic Effects of Exogenous and Endogenous Urotensin-II: Divergent Actions in Failing and Nonfailing Human Myocardium Circ Heart Fail, January 1, 2009; 2(1): 39 - 46. [Abstract] [Full Text] [PDF]

				A. E. S. Abdel-Razik, R. J. Balment, and N. Ashton Enhanced renal sensitivity of the spontaneously hypertensive rat to urotensin II Am J Physiol Renal Physiol, October 1, 2008; 295(4): F1239 - F1247. [Abstract] [Full Text] [PDF]

				J. P. Williams, J. P. Thompson, S. P. Young, S. J. Gold, J. McDonald, D. J. Rowbotham, and D. G. Lambert Nociceptin and urotensin-II concentrations in critically ill patients with sepsis Br. J. Anaesth., June 1, 2008; 100(6): 810 - 814. [Abstract] [Full Text] [PDF]

				C. Zoccali, F. Mallamaci, F. A. Benedetto, G. Tripepi, P. Pizzini, S. Cutrupi, and L. Malatino Urotensin II and Cardiomyopathy in End-Stage Renal Disease Hypertension, February 1, 2008; 51(2): 326 - 333. [Abstract] [Full Text] [PDF]

				W.H. Wilson Tang, G. S. Francis, D. A. Morrow, L. K. Newby, C. P. Cannon, R. L. Jesse, A. B. Storrow, R. H. Christenson, COMMITTEE MEMBERS, R. H. Christenson, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure Circulation, July 31, 2007; 116(5): e99 - e109. [Full Text] [PDF]

				E. Ovcharenko, Z. Abassi, I. Rubinstein, A. Kaballa, A. Hoffman, and J. Winaver Renal effects of human urotensin-II in rats with experimental congestive heart failure Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1205 - 1211. [Abstract] [Full Text] [PDF]

				E. Cowley, J. P. Thompson, P. Sharpe, J. Waugh, N. Ali, and D. G. Lambert Effects of pre-eclampsia on maternal plasma, cerebrospinal fluid, and umbilical cord urotensin II concentrations: a pilot study Br. J. Anaesth., October 1, 2005; 95(4): 495 - 499. [Abstract] [Full Text] [PDF]

				T. Watanabe, T. Suguro, T. Kanome, Y.-i. Sakamoto, S. Kodate, T. Hagiwara, S. Hongo, T. Hirano, M. Adachi, and A. Miyazaki Human Urotensin II Accelerates Foam Cell Formation in Human Monocyte-Derived Macrophages Hypertension, October 1, 2005; 46(4): 738 - 744. [Abstract] [Full Text] [PDF]

				S. G. Williams, L. L. Ng, R. J. O'Brien, S. Taylor, D. J. Wright, and L.-B. Tan Is plasma N-BNP a good indicator of the functional reserve of failing hearts? The FRESH-BNP study Eur J Heart Fail, December 1, 2004; 6(7): 891 - 900. [Abstract] [Full Text] [PDF]

				F. D. Russell, P. Kearns, I. Toth, and P. Molenaar Urotensin-II-Converting Enzyme Activity of Furin and Trypsin in Human Cells in Vitro J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 209 - 214. [Abstract] [Full Text] [PDF]

				M. Lim, S. Honisett, C. D. Sparkes, P. Komesaroff, A. Kompa, and H. Krum Differential Effect of Urotensin II on Vascular Tone in Normal Subjects and Patients With Chronic Heart Failure Circulation, March 16, 2004; 109(10): 1212 - 1214. [Abstract] [Full Text] [PDF]

				J. P. Thompson, P. Watt, S. Sanghavi, J. W. Strupish, and D. G. Lambert A Comparison of Cerebrospinal Fluid and Plasma Urotensin II Concentrations in Normotensive and Hypertensive Patients Undergoing Urological Surgery During Spinal Anesthesia: A Pilot Study Anesth. Analg., November 1, 2003; 97(5): 1501 - 1503. [Abstract] [Full Text] [PDF]

				I. Loke, I. B. Squire, J. E. Davies, and L. L. Ng Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate Eur J Heart Fail, October 1, 2003; 5(5): 599 - 606. [Abstract] [Full Text] [PDF]

				F. D. Russell, D. Meyers, A. J. Galbraith, N. Bett, I. Toth, P. Kearns, and P. Molenaar Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure Am J Physiol Heart Circ Physiol, October 1, 2003; 285(4): H1576 - H1581. [Abstract] [Full Text] [PDF]

				A. M.D. Watson, G. W. Lambert, K. J. Smith, and C. N. May Urotensin II Acts Centrally to Increase Epinephrine and ACTH Release and Cause Potent Inotropic and Chronotropic Actions Hypertension, September 1, 2003; 42(3): 373 - 379. [Abstract] [Full Text] [PDF]